Please login to the form below

Not currently logged in
Email:
Password:

type 2 diabetes

This page shows the latest type 2 diabetes news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

The deal - which includes $30m upfront and the remainder in milestone payments - is for IONIS-AZ6-2.5-LRx, an antisense drug that addresses an undisclosed target in NASH and is ... trial programme for the drug in NASH associated with type 2 diabetes.

Latest news

  • Merck KGaA inks deal for Medisafe adherence app Merck KGaA inks deal for Medisafe adherence app

    It is the first time the two companies have worked together and the initial project will cover drugs for type 2 diabetes, thyroid disorders and cardiovascular diseases. ... In diabetes for example adherence rates vary between 36% and 93%.

  • Novo's oral semaglutide ‘safe and well-tolerated’ Novo's oral semaglutide ‘safe and well-tolerated’

    PIONEER 1, oral semaglutide’s first phase III study, investigated its safety and efficacy in in adults with type 2 diabetes who took 3, 7 and 14mg doses of the drug ... II clinical trial in type 2 diabetes”.

  • After Axovant shock, Roivant pens diabetes deal with Poxel After Axovant shock, Roivant pens diabetes deal with Poxel

    After Axovant shock, Roivant pens diabetes deal with Poxel. Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal. ... by Merck Serono for type 2 diabetes, for $35m upfront and a $15m equity investment.

  • Takeda and Zinfandel abandon Alzheimer’s drug Takeda and Zinfandel abandon Alzheimer’s drug

    The TOMORROW study of low-dose pioglitazone - usually used to treat type 2 diabetes - was investigating whether it could delay the onset of mild cognitive impairment in early-stage AD, but ... Meanwhile, other diabetes drugs have also been tested for

  • Merck to pilot digital behavioural change programme Merck to pilot digital behavioural change programme

    Merck to pilot digital behavioural change programme. Will work with US digital therapeutics firm Blue Mesa Health in diabetes. ... Curtis Duggan, CEO at Blue Mesa Health, said: “We have seen such great success helping people across America prevent or

More from news
Approximately 29 fully matching, plus 457 partially matching documents found.

Latest Intelligence

  • Speech therapy Speech therapy

    The second looked at weight-loss coaching app Lark and showed that - if delivered properly - a chatbot style intervention could successfully support people at risk of type 2 diabetes both in

  • Positive disruption in business intelligence Positive disruption in business intelligence

    In an analysis of 47, 000 UK HCP posts about type 2 diabetes, 58% of mentions of named drugs were about drug trial data. ... While some high-profile clinical trials were mentioned by name during congress meetings, HCP mentions of drug trials in type 2

  • Managing medication non-adherence Managing medication non-adherence

    By targeting members who are likely to present with type 2 diabetes and other lifestyle-induced chronic illnesses if preventative action is not put in place, these plans have generated successful ... One Drop, the digital diabetes mHealth app, has

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia - would generate cost-savings in excess of £500m a year. ... type 2 diabetes, the latter was associated with significantly greater

  • The EarthWorks: New ways to improve patient care The EarthWorks: New ways to improve patient care

    Pharma should look beyond 'wellness' and basic proxy activity measures such as treatment steps and look instead at developing an end-to-end solution design for chronic conditions like type 2 ... care. We have designed programmes that are being piloted

More from intelligence
Approximately 5 fully matching, plus 31 partially matching documents found.

Latest appointments

  • Roche’s Torsten Hoffmann to join Zealand Pharma Roche’s Torsten Hoffmann to join Zealand Pharma

    In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity. ... Its lead product is the GLP-1 agonist lixisenatide, which is licensed to Sanofi who markets it

  • bmore creative hires Kush Rach as new business director bmore creative hires Kush Rach as new business director

    He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2 ... diabetes. Ben Blackmore, bmore creative's MD, told The Directory: "We are

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Getting personal with wearable tech

    In partnership with Diabetes UK and Hewlett Packard it is deploying mobile health self-management tools (wearable sensors and software) for people with Type 1 and Type 2 diabetes to

  • Evaluating the potential of a pre-launch prodct in a real-life setting

    Our client was developing a new product for treating Type 2 diabetes, which they were preparing for launch. ... In an increasingly competitive diabetes market, with new brands and formulations frequently becoming available, our client needed to determine

  • New insights into making behavioural change work

    Lifestyle conditions, or noncommunicable diseases (NCDs), include obesity, type 2 diabetes mellitus, cardiovascular disease and atherosclerosis [1]. ... References. 1. World Health Organization. Noncommunicable diseases (fact sheet 355). Available at: .

  • Dissecting adherence to personalise patient support

    Tailoring the approach to each distinct type. Distinguishing between the two types of non-adherence can better inform patient compliance efforts and clinical practice. ... IMS Institute for Healthcare Informatics (2016). Improving Type 2 Diabetes Therapy

  • Love Your Heart: An Innovative Interactive Video Programme

    Dr. John commented: “The increased risk of CVD for RA sufferers has the same level of severity as those who suffer with type 2 diabetes. ... calculate a QRISK® 2 score (a GP recognised prediction algorithm for CVD).

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics